Picchiassi Elena, Coata Giuliana, Babucci Giulia, Giardina Irene, Summa Valentina, Tarquini Federica, Centra Michela, Bini Vittorio, Cappuccini Benito, Di Renzo Gian Carlo
a Department of Obstetrics and Gynecology , University Hospital of Perugia , Perugia , Italy.
b Department of Internal Medicine , University Hospital of Perugia , Perugia , Italy.
J Matern Fetal Neonatal Med. 2018 Dec;31(24):3293-3300. doi: 10.1080/14767058.2017.1369041. Epub 2017 Aug 31.
The purpose of this study was to evaluate the potential improvement of introducing an intrapartum test for the detection of Group B Streptococcus (GBS) during labor and to estimate its cost-effectiveness versus antepartum GBS screening culture.
Three hundred and thirteen women at beginning of labor, with unknown GBS status or with antepartum GBS screening culture were enrolled. A vaginal-rectal specimen was collected from each woman for GBS detection by real-time PCR. Results of intrapartum test and antepartum GBS screening culture were compared.
Antepartum culture results did not always reflect the intrapartum maternal GBS colonization status since in 15.1% of the cases it was not concordant with intrapartum test. However, selecting only women, who underwent antepartum culture and intrapartum test at the same time, the percentage of concordance was 96.6%. Based on intrapartum test results, 74.9% of the total number of intrapartum antibiotic prophylaxis (IAP) was administered uselessly, while 1.9% of women did not receive IAP although they were positive to intrapartum test. Intrapartum test resulted less cost-effective than antepartum culture but it became more cost-effective at a cost threshold of about 16.00 €.
The clinical introduction of intrapartum test could be a valuable mean for identification of GBS colonization during labor, allowing an appropriate management of mothers and neonates with consequent benefit for their health and with limited costs for Healthcare System.
本研究的目的是评估在分娩期间引入检测B族链球菌(GBS)的产时检测的潜在改善情况,并估计其与产前GBS筛查培养相比的成本效益。
招募了313名分娩开始时GBS状态未知或进行过产前GBS筛查培养的女性。从每位女性采集阴道-直肠标本,通过实时PCR检测GBS。比较产时检测结果和产前GBS筛查培养结果。
产前培养结果并不总是反映产时母亲的GBS定植状态,因为在15.1%的病例中,它与产时检测结果不一致。然而,仅选择同时进行产前培养和产时检测的女性,一致性百分比为96.6%。根据产时检测结果,产时抗生素预防性使用(IAP)总数的74.9%使用不当,而1.9%的女性尽管产时检测呈阳性但未接受IAP。产时检测的成本效益低于产前培养,但在成本阈值约为16.00欧元时,其成本效益更高。
产时检测的临床应用可能是识别分娩期间GBS定植的有价值手段,可对母亲和新生儿进行适当管理,从而有益于他们的健康,同时对医疗保健系统的成本有限。